Therapeutic hepatitis B vaccine study using a two-part shot
Part of Digestive system, Infections clinical trials.
This trial tests a new vaccine to treat chronic hepatitis B. It's for people who have been on antiviral medication for at least 6 months and still have a low level of the virus in their blood.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had hepatitis B for at least 6 months and currently have a positive HBsAg test.
- You have been on antiviral medication for hepatitis B for at least 6 months.
- Your hepatitis B virus level in blood is very low (less than 100 IU/mL) on two separate tests in the last 6 months.
- You are between 18 and 70 years old.
- You do not have other serious liver disease, cirrhosis, or liver cancer.
- You have not received an MVA-based vaccine before (like a smallpox vaccine).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
This trial tests an experimental vaccine to help your immune system fight chronic hepatitis B, with the goal of controlling or possibly curing the infection. It's a early-stage study, so the main goals are safety and finding the right dose.
This study tests a two-step approach for chronic hepatitis B: first a shot called AHB-137, followed by another shot called TVAX-008. The goal is to see if this combination can help control the virus better.
This Phase 2 trial studies an injection (HRS-5635), either alone or with other medicines, to see if it is safe and helps keep chronic hepatitis B under control. It is for people who are already on standard hepatitis B antivirals and have low or undetectable viral levels.
This study tests a new combination of antiviral medicine and an immune-boosting therapy for adults with chronic hepatitis B. It is designed for people who are in the active phase of the infection and have not been treated before.
This trial tests a new treatment (GST-HG131&141 tablets) versus a placebo for people with chronic hepatitis B. It aims to see if the treatment can better control the virus in those already on stable therapy.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.